

**DOCKET NO.: 133087.11001 (101294-1P US)**

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: **Evertsson, Inghardt, Lindberg, Linusson, and Giordanetto**

Serial No.: **10/596,994**

Group Art Unit: **1625**

Filed: **November 22, 2006**

Examiner: **Nizal S. Chandrakumar**

Confirmation No.: **4275**

Title: **Therapeutic Agents I**

**Filed by EFS Web**

**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450


Dear Sir:

**RESPONSE TO THE RESTRICTION REQUIREMENT**

The present Response is filed in regard to the second Restriction Requirement dated June 5, 2008 in regard to the above-identified patent application.

The Examiner has restricted claims 1-11, 13, 15, and 17-21 into nine groups. Applicants elect Group 1 (containing claims 1-11, 13, 18, and 19; drawn to “compounds of formula I wherein L1 is mono or bicyclic carbocycle **unsubstituted except for the direct attachment of the two nitrogens bearing R3 and R4 moieties**” (emphasis in original)).

The Examiner also requests that Applicants elect a single species. Applicants elect (1S,3S)-N-(6-fluoro-4-methoxyquinolin-2-yl)-N'-(3-thienylmethyl)cyclohexane-1,3-diamine (see Example 5), the structure of which is shown below:



(1S,3S)-N-(6-fluoro-4-methoxyquinolin-2-yl)-N'-(3-thienylmethyl)cyclohexane-1,3-diamine

Claims 1-4, 6-8, 10, 11, and 13 read on the elected species.

Applicants submit that the present response is complete and complies with the requirements of 35 U.S.C. §121.

The Commissioner is hereby authorized to debit any underpayment of fee due or credit any overpayment to Deposit Account No. 50-0436.

Respectfully submitted,

/Paul K. Legaard, Reg.# 38534/

Paul K. Legaard, Ph.D.

Date: **July 2, 2008**

Pepper Hamilton LLP  
400 Berwyn Park  
899 Cassatt Road  
Berwyn, PA 19312-1183

Telephone: 610.640.7859  
Facsimile: 267.430.7647